T Turpeenniemi-Hujanen

Summary

Affiliation: Oulu University Hospital
Country: Finland

Publications

  1. ncbi request reprint Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers
    T Turpeenniemi-Hujanen
    Department of Oncology and Radiotherapy, Oulu University Hospital, PL22, 90029 OYS, Finland
    Biochimie 87:287-97. 2005
  2. pmc Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
    A Talvensaari-Mattila
    Department of Obstetrics and Gynecology, PO Box 5000, 90014, University of Oulu, Oulu, Finland
    Br J Cancer 89:1270-5. 2003
  3. pmc Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study
    Jenni K Peltonen
    Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland
    Head Neck Oncol 3:20. 2011
  4. pmc Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer
    Juho Konsti
    FIMM Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
    BMC Clin Pathol 11:3. 2011
  5. doi request reprint Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast
    E Rahko
    Department of Oncology and Radiotherapy, University Hospital of Oulu, Oulu, Finland eeva rahko ppshp fi
    Tumour Biol 30:257-64. 2009
  6. ncbi request reprint Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors
    M Määttä
    Department of Obstetrics and Gynecology, University of Oulu, Oulu, Finland
    Tumour Biol 25:188-92. 2004
  7. ncbi request reprint High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study
    P Kuvaja
    Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland
    Cancer Biomark 3:293-300. 2007
  8. ncbi request reprint Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor
    M Rauvala
    Department of Obstetrics and Gynecology, The University Hospital of Oulu, PL 24, FIN 90029 OYS, Oulu, Finland
    Gynecol Oncol 99:656-63. 2005
  9. ncbi request reprint Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer
    S Ylisirniö
    Departments of Oncology and Radiotherapy, Oulu University Hospital, FIN 90220 Oulu, Finland
    Clin Cancer Res 7:1633-7. 2001
  10. doi request reprint Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status
    P Kuvaja
    Department of Oncology and Radiotherapy, Institute of Clinical Medicine, Oulu University Hospital, Oulu, Finland
    Exp Cell Res 318:1094-103. 2012

Collaborators

  • Y Soini
  • M Santala
  • P Kuvaja
  • M Rauvala
  • S Ø Würtz
  • V L Kinnula
  • A Talvensaari-Mattila
  • P Paakko
  • Jenni K Peltonen
  • Juho Konsti
  • E Rahko
  • M Honkavuori
  • S Hoikkala
  • A Jukkola
  • M Määttä
  • R Mäkitaro
  • S Ylisirniö
  • Liisa Sailas
  • Heikki Joensuu
  • Tiina Lehtimäki
  • Kirsi H Vahakangas
  • Johan Lundin
  • Kaija Holli
  • Risto Bloigu
  • Vesa Kataja
  • Harri Sihto
  • Jorma Isola
  • Henni M Helppi
  • Mikael Lundin
  • Paavo Paakko
  • S Kauppila
  • M Apaja-Sarkkinen
  • G Blanco
  • U Puistola
  • J Risteli
  • P Pääakkö
  • G Blanco-Sequeiros
  • M Hoyhtya

Detail Information

Publications16

  1. ncbi request reprint Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers
    T Turpeenniemi-Hujanen
    Department of Oncology and Radiotherapy, Oulu University Hospital, PL22, 90029 OYS, Finland
    Biochimie 87:287-97. 2005
    ..The growing amount of recent clinical data suggests that the impact of gelatinases on treatment decisions should be tested in clinical trials...
  2. pmc Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
    A Talvensaari-Mattila
    Department of Obstetrics and Gynecology, PO Box 5000, 90014, University of Oulu, Oulu, Finland
    Br J Cancer 89:1270-5. 2003
    ..MMP-2 is also shown to correlate to shortened survival independent of major prognostic indicators in patients with primary breast carcinoma...
  3. pmc Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study
    Jenni K Peltonen
    Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland
    Head Neck Oncol 3:20. 2011
    ..Despite the intense research in the area of squamous cell carcinomas of head and neck (HNSCC), long-term survival rate has not changed significantly in this malignancy during recent decades...
  4. pmc Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer
    Juho Konsti
    FIMM Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
    BMC Clin Pathol 11:3. 2011
    ..abstract:..
  5. doi request reprint Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast
    E Rahko
    Department of Oncology and Radiotherapy, University Hospital of Oulu, Oulu, Finland eeva rahko ppshp fi
    Tumour Biol 30:257-64. 2009
    ..Tissue inhibitor 1 of MMP (TIMP-1) is a strong inhibitor of MMP-9 but has also tumor-enhancing effects. Only few data exist on MMP-9 or TIMP-1 expression in tissue samples of different breast histology...
  6. ncbi request reprint Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors
    M Määttä
    Department of Obstetrics and Gynecology, University of Oulu, Oulu, Finland
    Tumour Biol 25:188-92. 2004
    ....
  7. ncbi request reprint High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study
    P Kuvaja
    Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland
    Cancer Biomark 3:293-300. 2007
    ..However, including information of the level of uncomplexed TIMP-1 did not seem to provide additional prognostic information to that already provided by total TIMP-1...
  8. ncbi request reprint Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor
    M Rauvala
    Department of Obstetrics and Gynecology, The University Hospital of Oulu, PL 24, FIN 90029 OYS, Oulu, Finland
    Gynecol Oncol 99:656-63. 2005
    ....
  9. ncbi request reprint Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer
    S Ylisirniö
    Departments of Oncology and Radiotherapy, Oulu University Hospital, FIN 90220 Oulu, Finland
    Clin Cancer Res 7:1633-7. 2001
    ....
  10. doi request reprint Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status
    P Kuvaja
    Department of Oncology and Radiotherapy, Institute of Clinical Medicine, Oulu University Hospital, Oulu, Finland
    Exp Cell Res 318:1094-103. 2012
    ..This might suggest that breast cancer cells can take up TIMP-1 produced by stromal cells and are thus displaying cellular immunoreactivity. In addition, TIMP-1 was shown to improve stratification of prognosis in clinical material...
  11. ncbi request reprint Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression
    M Rauvala
    Department of Obstetrics and Gynecology, The University Hospital of Oulu, PL 24, FIN 90029 OYS, Oulu, Finland
    Int J Gynecol Cancer 16:1297-302. 2006
    ..Intensive MMP-9 was noted in grade 1 tumors. We conclude that MMP-2 and MMP-9 have different roles in uterine cervical cancer. MMP-2 could be associated with aggressive behavior, but MMP-9 expression diminishes in high-grade tumors...
  12. ncbi request reprint Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy
    A Talvensaari-Mattila
    Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Finland
    Breast Cancer Res Treat 65:55-61. 2001
    ..It might have predictive value in selecting the most efficient adjuvant therapy in this set of patients...
  13. ncbi request reprint Matrix metalloproteinase 9 and relapse in patients with early stage squamous cervical carcinoma
    A Talvensaari-Mattila
    Department of Obstetrics and Gynecology, Oulu University Hospital, Box 24, 90029 OYS, Oulu, Finland
    Int J Gynaecol Obstet 91:75-6. 2005
  14. ncbi request reprint MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma
    M Honkavuori
    Department of Obstetrics and Gynecology, PO Box 5000, University of Oulu, Oulu 90014, Finland
    Gynecol Oncol 104:217-21. 2007
    ..This study aimed to evaluate the roles of matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) as prognostic factors in endometrial carcinoma and their association with CA 125 and other conventional prognostic markers...
  15. ncbi request reprint Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma
    S Hoikkala
    Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, P O Box 22, FIN 90029 OYS, Finland
    Cancer Lett 236:125-32. 2006
    ..We conclude that in lung carcinoma the best prognostic value is achieved by using immunohistochemistry for MMP-2 and MMP-9. In early disease, however, serum TIMP-1 or MMP-2/TIMP-2-complex could offer some further prognostic value...
  16. ncbi request reprint Matrix metalloproteinase 9 in the uterine cervix during tumor progression
    A Talvensaari-Mattila
    Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland
    Int J Gynaecol Obstet 92:83-4. 2006